HOXA5 is amplified in glioblastoma stem cells and promotes tumor progression by transcriptionally activating PTPRZ1. (1st May 2022)

• Record Type: Journal Article
• Authors: He, Zhi-Cheng; Liu, Qing; Yang, Kai-Di; Chen, Cong; Zhang, Xiao-Ning; Wang, Wen-Ying; Zeng, Hui; Wang, Bin; Liu, Yu-Qi; Luo, Min; Li, Lei; Niu, Qin; Lu, Hui-Min; Luo, Tao; Yao, Xiao-Hong; Guo, Hai-Tao; Ji, Jia-Le; Cao, Mian-Fu; Shi, Yu; Ping, Yi-Fang; Bian, Xiu-Wu
• Is Part Of: Cancer letters. Volume 533(2022)
• Publication Date: 2022-05-01
• Subjects: HomeoboxA5 -- Glioma stem cell -- Protein tyrosine phosphatase receptor type Z1 -- Gene amplification; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.canlet.2022.215605
• Languages: English
• ISSNs: 0304-3835

Abstract

Abstract: Although the tumorigenic potential of glioma stem cells (GSCs) is associated with multiple molecular alterations, the gene amplification status of GSCs has not been elucidated. Overexpression of HomeoboxA5 ( HOXA5 ) is associated with increased glioma malignancy. In this study, we identify the gene amplification and protein overexpression of HOXA5 in GSCs and its function in regulating GSC maintenance and the downstream transcriptional effector, to explore the significance of HOXA5 amplification/overexpression for GSC identification and prognostic determination. The HOXA5 gene is significantly amplified in glioblastoma (GBM) and is an independent prognostic factor for predicting worse patient outcomes. Specifically, HOXA5 gene amplification and the resultant protein overexpression are correlated with increased proportions of GSCs and enhanced self-renewal/invasiveness of these cells. Disruption of HOXA5 expression impairs GSC survival and GBM tumor propagation. Mechanistically, HOXA5 directly binds to the promoter region of protein tyrosine phosphatase receptor type Z1 ( PTPRZ1 ), thereby upregulating this gene for GSC maintenance. Suppression of PTPRZ1 largely compromises the pro-tumoral effect of HOXA5 on GSCs. In summary, HOXA5 amplification serves as a genetic biomarker for predicting worse GBM outcome, by enhancing PTPRZ1 -mediated GSC survival. Highlights: HOXA5 is amplified in GBM and predicts poor patient prognosis. HOXA5 transcriptionally activates PTPRZ1 to enhance GSC self-renewal and invasiveness. HOXA5 gene amplification could help for personalized molecular diagnosis and targeted therapy.